In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
Transformation to pure-play Innovative Medicines company nears completion
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Dr Sai Satish, Sr. Consultant Interventional Cardiologist performs India’s first 3 successful G4-Transcatheter Edge to Edge (G4–TEER) mitral valve repairs
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Subscribe To Our Newsletter & Stay Updated
